Isentress.

McGill University Health Centre/Research Institute of the McGill University Health Centre · FDA-approved active Small molecule Quality 5/100

Isentress. is a Small molecule drug developed by McGill University Health Centre/Research Institute of the McGill University Health Centre. It is currently FDA-approved. Also known as: Raltegravir.

Isentress is a small molecule medication used to treat HIV-1 infection. It is a brand name for the active ingredient Raltegravir, which is a treatment for HIV-1 infection.

At a glance

Generic name	Isentress.
Also known as	Raltegravir
Sponsor	McGill University Health Centre/Research Institute of the McGill University Health Centre
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen (PHASE4)
• Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
• A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
• Pregnancy, Anti-integrase and Lymphocyte Repertoire of the Newborn
• Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
• Therapeutic Drug Monitoring to oPtimize ANtiretroviral regimeNs in HIV-infected Women Who wAnt to Breastfeed
• Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
• Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Isentress. CI brief — competitive landscape report
• Isentress. updates RSS · CI watch RSS
• McGill University Health Centre/Research Institute of the McGill University Health Centre portfolio CI

Frequently asked questions about Isentress.

What is Isentress.?

Isentress. is a Small molecule drug developed by McGill University Health Centre/Research Institute of the McGill University Health Centre.

Who makes Isentress.?

Isentress. is developed and marketed by McGill University Health Centre/Research Institute of the McGill University Health Centre (see full McGill University Health Centre/Research Institute of the McGill University Health Centre pipeline at /company/mcgill-university-health-centre-research-institute-of-the-mcgill-university-heal).

Is Isentress. also known as anything else?

Isentress. is also known as Raltegravir.

What development phase is Isentress. in?

Isentress. is FDA-approved (marketed).

Related

• Manufacturer: McGill University Health Centre/Research Institute of the McGill University Health Centre — full pipeline
• Also known as: Raltegravir